skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Pegylated Liposomal Irinotecan (Code C62789)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Pegylated Liposomal Irinotecan

Definition: A formulation of polyethylene glycol (PEG)-modified liposomes encapsulating the semisynthetic derivative of camptothecin irinotecan, with antineoplastic activity. As a prodrug, irinotecan is converted to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. In turn, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex of topoisomerase I and DNA, resulting in DNA breaks. This results in an inhibition of DNA replication and an induction of apoptosis. Pegylated liposomal delivery of irinotecan improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of exposure while lowering systemic toxicity.

Display Name: Pegylated Liposomal Irinotecan

Label: Pegylated Liposomal Irinotecan

NCI Thesaurus Code: C62789 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831956  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Pegylated Liposomal Irinotecan

External Source Codes: 
PDQ Closed Trial Search ID 506099
PDQ Open Trial Search ID 506099 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831956

Other Properties:
     Name Value (qualifiers indented underneath)
code C62789
Contributing_Source CTRP
Legacy_Concept_Name Liposomal_Irinotecan
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom